Benzinga · Sep 8, 2026
Wedbush Reiterates Outperform on argenx, Maintains $1150 Price Target
Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintains $1150 price target.
AR
NASDAQ · ARGX
argenx SE
Healthcare · Biotechnology
$979.76
Down-$10.78 (-1.09%)
Updated Sep 16, 2026, 10:34 AM
SID Score
6.4/10
Composite research score
Smart Money
60/100
Neutral
- Market cap
- 47.46B
- P/E ratio
- 42.26
- Dividend yield
- 0.00%
- 52-week range
- $661.85 – $1,072.75
- Volume
- 235.3K
- Avg. volume
- 347.54K
Price performance
ARGX price history
1M range · 20 trading sessions · Daily adjusted prices
ARGX closed at $979.76 after 20 trading sessions, down 1.33% for the selected period.
- Last close
- $979.76
- Period change
- -1.33%
- Period low
- $979.76
- Period high
- $1,058.90
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $985.87 | $1,000.59 | $977.03 | $979.76 | 235.3K |
| Sep 14, 2026 | $1,004.56 | $1,008.32 | $988.40 | $990.54 | 198.6K |
| Sep 11, 2026 | $1,001.62 | $1,002.95 | $983.10 | $984.39 | 181.88K |
| Sep 10, 2026 | $991.05 | $1,000.24 | $981.74 | $984.04 | 226.47K |
| Sep 9, 2026 | $991.68 | $1,008.93 | $988.69 | $1,002.31 | 209.93K |
| Sep 8, 2026 | $1,005.68 | $1,015.79 | $995.00 | $1,007.07 | 313.88K |
| Sep 4, 2026 | $1,040.31 | $1,048.435 | $1,031.19 | $1,033.15 | 125.06K |
| Sep 3, 2026 | $1,070.81 | $1,070.81 | $1,052.78 | $1,053.46 | 210.44K |
| Sep 2, 2026 | $1,049.46 | $1,072.75 | $1,042.22 | $1,055.37 | 216.99K |
| Sep 1, 2026 | $1,033.36 | $1,039.13 | $1,021.5501 | $1,028.51 | 192.94K |
| Aug 31, 2026 | $1,010.78 | $1,039.36 | $1,005.78 | $1,031.66 | 227.99K |
| Aug 28, 2026 | $1,049.87 | $1,053.00 | $1,018.60 | $1,023.21 | 175.52K |
| Aug 27, 2026 | $1,053.47 | $1,061.57 | $1,044.76 | $1,058.90 | 322.52K |
| Aug 26, 2026 | $1,033.83 | $1,057.91 | $1,032.85 | $1,047.10 | 362.1K |
| Aug 25, 2026 | $1,020.29 | $1,030.3599 | $1,013.75 | $1,019.49 | 142.23K |
| Aug 24, 2026 | $1,023.76 | $1,031.18 | $1,001.505 | $1,011.11 | 318.43K |
| Aug 21, 2026 | $1,034.98 | $1,058.69 | $1,029.46 | $1,039.78 | 377.3K |
| Aug 20, 2026 | $1,019.16 | $1,039.30 | $1,018.98 | $1,038.12 | 258.3K |
| Aug 19, 2026 | $1,020.51 | $1,035.09 | $1,011.95 | $1,032.86 | 390.89K |
| Aug 18, 2026 | $988.49 | $1,009.745 | $980.45 | $992.99 | 333.94K |
Latest ARGX news
The latest Smart Investors Daily articles mentioning ARGX.
Stock researchCompany · Overview
ARGX research
Overview
Company profile and research snapshot.
Company profile
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $967.36
- Implied upside
- —
- Analysts
- 9
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Jul 12, 2026 | TD COWEN | Buy | — |
| Jul 12, 2026 | DAY BY DAY | Buy | — |
| Jul 1, 2026 | KBC SECURITIES | Buy | — |
| Jun 24, 2026 | H.C. WAINWRIGHT & CO., LLC | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 4, 2026
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.58% on an annualized basis producing an average annual return of 24.86%. Currently, argenx has a market capitalization of $64.63 billion.
Benzinga · Sep 3, 2026
Wedbush Reiterates Outperform on argenx, Maintains $1150 Price Target
Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintains $1150 price target.
Yahoo · Sep 2, 2026
BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
TORONTO, September 02, 2026--BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation led by argenx's own scientists, the agreement represents a significant milestone in BenchSci's expansion across European biopharma.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
